Summary by Futu AI
KOCHI PHARMACEUTICAL-B (THE “COMPANY”) ANNOUNCED THAT ITS DEVELOPED CT041 CLINICAL TRIAL DATA WILL BE REPORTED ORALLY AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) IN 2024. CT041 is an autologous CAR-T cell candidate for Claudin18.2 protein that is primarily used in the treatment of gastric cancer, gastroesophageal combined prostate cancer and pancreatic cancer. The summary of this report will be published on 23 May 2024 and the oral report will be made on 3 June of the same year. CT041 has been conducted in several clinical trials in China and North America and has been recognized as a “Regenerative Medicine Advanced Therapeutics” by the US FDA and a “Preferred Drug” status by the European Medicines Agency. With a focus on CAR-T cell therapy, Kozin Pharmaceuticals aims to be a global leader in biopharmaceuticals to improve treatment safety, efficacy and lower costs.